ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

VIGL Vigil Neuroscience Inc

3.03
0.29 (10.58%)
After Hours
Last Updated: 06:46:47
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Vigil Neuroscience Inc VIGL NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.29 10.58% 3.03 06:46:47
Open Price Low Price High Price Close Price Previous Close
2.72 2.67 3.05 3.03 2.74
more quote information »

Recent News

Date Time Source Heading
18/4/202406:05GLOBEVigil Presents Key Findings from ILLUMINATE & IGNITE Studies..
26/3/202422:05GLOBEVigil Neuroscience Reports Fourth Quarter and Full Year 2023..
20/3/202422:05GLOBEVigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief..
13/3/202422:05GLOBEVigil Announces Upcoming Presentations at 2024 American..
12/3/202422:05GLOBEVigil Neuroscience to Present at Stifel 2024 Virtual CNS..
07/3/202408:25GLOBEVigil Announces Oral Presentation on Small Molecule TREM2..
02/3/202410:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202409:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202408:05GLOBEVigil Presents Poster on Impacts of Misdiagnosis and Genetic..
15/2/202403:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202408:05GLOBEVigil Neuroscience to Present at Guggenheim 6th Annual..
12/1/202402:30EDGAR2Form 8-K - Current report
04/1/202408:30GLOBEVigil Neuroscience Provides 2023 Year-in-Review and..
23/11/202308:05GLOBEVigil Neuroscience to Present at Evercore ISI 6th Annual..
17/11/202308:31EDGAR2Form 8-K - Current report
17/11/202308:05GLOBEVigil Neuroscience Reports Positive Interim Data from Phase..
07/11/202323:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202323:15EDGAR2Form 8-K - Current report
07/11/202323:05GLOBEVigil Neuroscience Reports Third Quarter 2023 Financial..
17/10/202322:05GLOBEVigil Neuroscience Announces First Participant Dosed in..
13/10/202307:06EDGAR2Form 8-K - Current report
06/10/202307:01GLOBEVigil Neuroscience to Present at Jefferies Inaugural Biotech..
26/9/202321:05GLOBEVigil Neuroscience Receives Positive Opinion from European..
13/9/202321:31EDGAR2Form 8-K - Current report
12/9/202302:00GLOBEVigil Neuroscience Presents VGL101 Complete Phase 1 Data and..
09/9/202306:10EDGAR2Form 8-K - Current report
09/9/202306:05GLOBEVigil Neuroscience Announces Update on its Small Molecule..
08/9/202321:05GLOBEVigil Neuroscience to Present at 2023 Morgan Stanley Global..
08/8/202321:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202321:19EDGAR2Form 8-K - Current report
08/8/202321:05GLOBEVigil Neuroscience Reports Second Quarter 2023 Financial..
08/8/202308:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202308:38EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/8/202306:05GLOBEVigil Neuroscience Appoints Christopher J. Silber, M.D. as..
01/6/202321:00GLOBEVigil Neuroscience to Present at 2023 Jefferies Global..
10/5/202321:00GLOBEVigil Neuroscience Reports First Quarter 2023 Financial..
09/5/202321:00GLOBEVigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D...
08/5/202321:08GLOBEVigil Neuroscience Launches ALSPAware to Provide Access to..

Your Recent History

Delayed Upgrade Clock